证券代码：688105 证券简称：诺唯赞 公告编号：2023-026 南京诺唯赞生物科技股份有限公司 关于公司董事长兼总经理、实际控制人 提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到公司董事长兼总经理、实际控制人曹林先生《关于提议南京诺唯赞生物科 技股份有限公司回购公司股份的函》，提议主要内容如下： 一、提议回购股份的原因和目的 曹林先生基于对公司未来发展的信心和对公司价值的认可，为充分激发公司 员工积极性，持续建立公司长效激励机制，并增强投资者对公司的投资信心，紧 密结合公司利益、股东利益与员工利益，促进公司健康可持续发展，根据相关法 律法规，提议公司以集中竞价交易方式回购部分公司股份，并将全部用于公司股 权激励或员工持股计划。 二、提议内容 （一）回购股份的种类及回购方式：通过上海证券交易所股票交易系统以集 中竞价交易方式回购公司已发行的人民币普通股（A 股）。 （二）回购股份的用途：用于股权激励或 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2023-023 南京诺唯赞生物科技股份有限公司 关于参加2022年度生物制品专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 6 月 13 日(星期二)16:00 前通过公司邮箱 irm@vazyme.com 进行提问。公司将在文字互动环节对投资者普遍关注的问题进行回答。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告。为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况、发展理念，公司参与了由上海证券交易所主办的 2022 年度 生物制品专场集体业绩说明会，此次活动将采用视频和线上文字互动的方式举行， 投资者可登录上海证券交易所上证路演中心（roadshow.sseinfo.com）参与线上互 动交流。 一、说明会类型 本次投资者说明会以视频和网络互动形式召开，公司将针对 2022 年度的经营成 果及财务指标的具体 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥302,194,310.54, representing a decrease of 69.02% compared to the same period last year [4] - The net profit attributable to shareholders was a loss of ¥50,623,311.46, down 111.74% year-over-year [4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥75,125,845.29, a decline of 118.21% compared to the previous year [4] - The weighted average return on net assets was -1.10%, a decrease of 11.03 percentage points year-over-year [4] - Net profit for Q1 2023 was a loss of ¥51,208,589.27, compared to a profit of ¥431,359,398.28 in Q1 2022, indicating a substantial decline [42] - Basic earnings per share for Q1 2023 were -¥0.13, compared to ¥1.08 in Q1 2022 [44] - Total comprehensive income for Q1 2023 was a loss of ¥49,774,329.40, compared to a profit of ¥431,359,398.28 in Q1 2022 [44] Cash Flow - The net cash flow from operating activities was a negative ¥109,073,393.58, reflecting a decrease of 249.97% year-over-year [4] - The net cash flow from operating activities for Q1 2023 was -109,073,393.58 RMB, a significant decline compared to 72,730,459.02 RMB in Q1 2022 [46] - The cash outflow from operating activities in Q1 2023 was 701,550,351.36 RMB, compared to 902,096,258.18 RMB in Q1 2022 [46] - The cash inflow from sales of goods and services in Q1 2023 was 578,212,675.41 RMB, a decrease from 957,700,806.54 RMB in Q1 2022 [46] - The company's cash inflow from operating activities totaled approximately ¥495.12 million in Q1 2023, compared to ¥365.66 million in Q1 2022, an increase of 35.4% [64] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,318,386,126.23, up 5.22% from the end of the previous year [6] - The equity attributable to shareholders decreased by 1.30% to ¥4,548,926,459.63 compared to the end of the previous year [6] - Total liabilities increased to approximately 1.77 billion from 1.39 billion [27] - The total liabilities as of March 31, 2023, were 1,263,943,027.74 RMB, an increase from 865,529,991.86 RMB at the end of 2022 [50] - The total owner's equity as of March 31, 2023, was 4,729,042,013.18 RMB, slightly up from 4,713,043,471.29 RMB at the end of 2022 [50] Research and Development - Research and development expenses totaled ¥84,907,590.77, an increase of 19.32% compared to the same period last year [4] - R&D expenses accounted for 28.10% of operating revenue, an increase of 20.80 percentage points year-over-year [6] - Research and development expenses increased to ¥84,907,590.77 in Q1 2023, up 19.4% from ¥71,157,250.07 in Q1 2022 [41] - Research and development expenses for Q1 2023 were approximately ¥58.63 million, up from ¥49.00 million in Q1 2022, representing an increase of 19.6% [62] Other Income and Expenses - Other income increased by 337.69%, mainly due to an increase in government subsidies received compared to the same period last year [19] - Financial expenses surged by 1,934.82%, influenced by the scale of bank loans and exchange rate fluctuations [19] - The company reported non-recurring gains of ¥16,100,662.32 during the period [17] - The company's financial expenses showed a decrease, with interest expenses recorded at approximately ¥3.80 million in Q1 2023, compared to ¥3.23 million in Q1 2022 [62] - The company's other income increased to approximately ¥3.32 million in Q1 2023 from ¥2.83 million in Q1 2022, reflecting a growth of 17.3% [62] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,952, with the largest shareholder holding 40.48% [32]

Financial Performance - The company achieved a total revenue of 3.569 billion RMB in 2022, representing a year-on-year growth of 90.99%[8] - The net profit attributable to shareholders was 594 million RMB, a decrease of 12.39% compared to the previous year[8] - The company reported a net cash flow from operating activities of 607 million RMB in Q4 2022[1] - The company’s conventional business, including research reagents and diagnostic materials, generated sales revenue of 1.014 billion RMB, a growth of 41.03% year-on-year[8] - The company’s financial assets at fair value decreased by 256.58 million RMB during the reporting period[5] - The company’s government subsidies recognized in the current period amounted to 15.81 million RMB[2] - The company achieved a sales revenue of 1.468 billion CNY in 2022 for its in vitro diagnostic business, with a 37.08% year-on-year growth in conventional business revenue[48] - The company plans to distribute a cash dividend of 12.50 RMB per 10 shares, totaling 500.13 million RMB, which represents 84.14% of the net profit attributable to shareholders for the year 2022[101] - The total share capital of the company as of December 31, 2022, is 400.01 million shares[101] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[102] - The company has received a standard unqualified audit opinion from the accounting firm[105] Research and Development - Research and development expenses for 2022 amounted to 396 million RMB, an increase of 71.98% year-on-year[9] - The total number of R&D personnel reached 1,196, which is an increase of 83.44% year-on-year, accounting for 29.20% of the total workforce[9] - The company filed 97 patent applications during the reporting period, with 46 patents granted[9] - The mRNA vaccine platform has overcome several technical barriers, enabling the development and production of high-quality mRNA raw materials, with over a thousand rounds of testing completed[37] - The company has filed two patents for innovative raw materials related to mRNA vaccine production, enhancing its competitive edge in the market[37] - The company has developed over 40 ELISA test kits and 170 pseudovirus products for evaluating immune responses to COVID-19 vaccines, providing comprehensive solutions for downstream vaccine enterprises[34] - The company has developed core enzyme raw materials and related kits for mRNA vaccine production, ensuring compliance and high-quality supply[81] - The company emphasizes talent development through various training programs and a diverse recruitment strategy to enhance employee capabilities[75] - The company is focused on expanding its technology platform to include mRNA vaccines and related applications, responding quickly to public health events like COVID-19[147][160] - The company has established a key common technology platform based on multiple disciplines, allowing for diverse R&D directions and rapid product development[147] Product Development and Innovation - The company launched nearly 300 new products in the life sciences sector, including advancements in PCR and NGS technologies[14] - The company launched a new series of pre-mixed fluorescent quantitative reagents for clinical diagnostics and animal inspection, achieving high efficiency and sensitivity in detection with a rapid testing time of 10-40 minutes[17] - The new pre-mixed solution supports multiple target detection and includes a dUTP/UDG contamination prevention system, significantly reducing false positives[19] - The company introduced a comprehensive methylation solution in high-throughput sequencing reagents, which includes extraction, library construction, and methylation conversion reagents, improving conversion efficiency and reducing processing time[21] - The new multiplex amplification reagents for tNGS technology enable accurate and rapid detection of various pathogens, compatible with both DNA and RNA testing[23] - The company expanded its product line in the biopharmaceutical sector, developing nearly 70 terminal products, including cell activity detection and residual testing reagents[31] - The company has established a comprehensive POCT product line, focusing on cardiovascular, inflammatory infection, and other diagnostic areas[48] - The company has launched new drug development reagents and vaccine evaluation reagents, including the Add & ReadTM series compatible with high-throughput operations[81] - The company has developed a series of quality control products, such as the cardiac troponin I quality control product, to ensure the reliability of its testing solutions[50][73] Market Expansion and Strategy - The company has set up subsidiaries in Hong Kong, the USA, Indonesia, Singapore, and Germany to enhance its international business presence[49] - The company is actively expanding its international business, with over 160 employees in its international business department and a focus on localizing operations in various countries[51] - The company enhanced its marketing system and increased market share by expanding the sales team in mature regions and strengthening the sales network in resource-rich provinces, resulting in improved customer satisfaction and market penetration in the life sciences sector[52] - In the biopharmaceutical segment, the company transformed its marketing model to focus on long-term partnerships with clients, shifting from product sales to integrated solutions, which has driven deeper collaboration and increased customer engagement[54] - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence and product offerings[122] - The company is focusing on expanding its market presence through localized sales and technical support, leveraging its strengths in key product categories[91] Compliance and Risk Management - The company has outlined significant risk factors that may adversely affect its operations in the management discussion section[104] - The company faces regulatory risks due to increasing scrutiny in the medical device industry, which could impact operational performance if not managed effectively[176] - The company faces risks related to product development and technology iteration, which could impact its core competitiveness if not managed effectively[155] Industry Trends and Market Insights - The global in vitro diagnostics (IVD) market size grew from $48.4 billion in 2015 to $60.2 billion in 2019, with a projected CAGR of 6.9% reaching $84 billion by 2024[175] - China's IVD market size increased from ¥36.6 billion in 2015 to ¥86.4 billion in 2019, with an expected CAGR of 17.8% to reach ¥195.7 billion by 2024[175] - The market for IVD raw materials in China expanded from ¥3.3 billion in 2015 to ¥8.2 billion in 2019, with a CAGR of 25.8%, projected to reach ¥20 billion by 2024[178] - The POCT market in China grew from ¥4.3 billion in 2015 to ¥11.2 billion in 2019, with a CAGR of 27.0%, expected to reach ¥29 billion by 2024[183] - The domestic IVD raw materials market is expected to grow at a CAGR of 23.3%, reaching ¥2.7 billion by 2024, indicating a shift towards import substitution[181] - The global biopharmaceutical market size was approximately $286.4 billion in 2019, projected to reach $456.7 billion by 2024, with a compound annual growth rate (CAGR) of 9.78%[185] - China's biopharmaceutical market grew from 183.6 billion RMB in 2016 to 369.7 billion RMB in 2020, with a CAGR of 19.1%, expected to reach 812.2 billion RMB by 2025[185]

证券简称：诺唯赞 证券代码：688105 1 南京诺唯赞生物科技股份有限公司 投资者关系活动记录表 编号：2022-04 | --- | --- | |-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券简称：诺唯赞 证券代码：688105 1 南京诺唯赞生物科技股份有限公司 投资者关系活动记录表 编号：2022-03 | --- | --- | |-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥685,295,138.79, representing a year-on-year increase of 47.99%[8] - The net profit attributable to shareholders for Q3 2022 was ¥135,794,073.16, a decrease of 14.25% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥121,885,460.27, down 19.73% year-on-year[8] - The total revenue for the first three quarters of 2022 reached ¥2,305,008,853.45, an increase of 78.87% year-on-year[8] - Operating profit for the third quarter of 2022 was ¥846,493,380.05, compared to ¥625,708,909.12 in the previous year, indicating an increase of about 35.2%[39] - Net profit attributable to shareholders of the parent company for the third quarter of 2022 was ¥749,497,519.33, up from ¥550,217,138.59 in the same quarter of 2021, reflecting a growth of approximately 36.2%[39] - Total comprehensive income attributable to the parent company was ¥749,735,147.00, compared to ¥550,217,138.59 in the previous year, representing an increase of approximately 36.3%[42] - Basic and diluted earnings per share were both ¥1.87, up from ¥1.53 in the same period last year, indicating a growth of 22.2%[42] Research and Development - The company’s R&D expenses for Q3 2022 amounted to ¥112,946,153.19, a significant increase of 78.36% year-on-year[12] - The proportion of R&D expenses to operating revenue was 16.48%, an increase of 2.81 percentage points compared to the same period last year[12] - Research and development expenses for the first three quarters of 2022 totaled ¥269,896,412.14, compared to ¥147,863,826.86 in the same period of 2021, marking an increase of about 82.3%[37] - Research and development expenses increased to ¥184,578,549.97 in the first three quarters of 2022, compared to ¥101,008,979.48 in 2021, indicating a focus on innovation[54] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥5,885,116,758.19, reflecting a year-on-year increase of 27.74%[12] - Total assets increased to RMB 5,885,116,758.19 as of September 30, 2022, up from RMB 4,607,119,884.54 at the end of 2021, representing a growth of approximately 27.8%[28] - The total liabilities for the company were reported at ¥776,991,325.54, compared to ¥363,741,923.70 in the previous year, indicating increased leverage[54] - Total liabilities as of the end of the reporting period amounted to ¥1,118,788,554.03, a significant rise from ¥479,829,915.56 in the previous year, indicating an increase of approximately 133.3%[37] - The company reported a significant increase in non-current assets, totaling RMB 1,601,746,485.10, compared to RMB 556,231,936.56 in the previous year[28] Cash Flow - The net cash flow from operating activities for the first three quarters was ¥127,862,604.78, down 57.28% year-on-year[12] - Cash inflow from operating activities totaled ¥2,142,954,800.17, significantly higher than ¥1,191,583,831.89 in the previous year, marking an increase of approximately 79.9%[46] - Cash outflow from operating activities was ¥2,015,092,195.39, compared to ¥892,309,967.96 in the previous year, reflecting a rise of about 125.4%[46] - Cash inflows from investment activities amounted to approximately ¥5.73 billion in the first three quarters of 2022, compared to ¥3.51 billion in the same period of 2021, representing an increase of about 63.1%[63] - The net cash flow from investment activities was negative at approximately -¥465 million in the first three quarters of 2022, slightly improved from -¥501 million in the same period of 2021[63] - Cash inflows from financing activities were ¥300 million in the first three quarters of 2022, with a net cash flow of approximately ¥78.30 million, compared to a net outflow of -¥24.22 million in the same period of 2021[63] Strategic Investments - The company acquired an 83.93% stake in Jiangsu Liquid Logic Biotechnology Co., Ltd. after investing RMB 121 million[26] - The establishment of Vazyme Germany GmbH was completed with a registered capital of €300,000, fully owned by the company[26] - The company secured land use rights for a plot of state-owned land for RMB 32.1 million[26] - The company’s total equity position improved, reflecting its strategic investments and acquisitions during the reporting period[26] Other Financial Metrics - The weighted average return on net assets was 2.45%, a decrease of 6.25 percentage points compared to the previous year[12] - Cash and cash equivalents decreased to RMB 953,491,183.60 from RMB 1,477,779,597.50, a decline of about 35.4%[28] - Accounts receivable rose significantly to RMB 645,516,612.62, compared to RMB 322,319,587.08, marking an increase of approximately 100.2%[28] - Inventory surged to RMB 672,014,593.32, up from RMB 242,188,912.54, reflecting an increase of around 177.5%[32] - The company's financial expenses showed a reversal, with a net income of -¥9,594,145.71 in the third quarter of 2022, compared to an expense of ¥2,802,898.36 in the same quarter of 2021[39] - Deferred income tax liabilities increased to ¥39,889,122.45 from ¥874,400.28, indicating a substantial rise[37] - The company reported a significant increase in sales expenses, which totaled ¥345,477,321.85 in the third quarter of 2022, compared to ¥201,487,568.14 in the same quarter of 2021, reflecting an increase of approximately 71.2%[37]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 500 million, representing a growth of 25% year-over-year[2]. - The company reported a significant increase in revenue, achieving a total of $500 million for the quarter, representing a 25% year-over-year growth[18]. - The company reported a net profit of $80 million, a 30% increase compared to the same period last year[20]. - The company's operating revenue for the first half of 2022 was CNY 1,619,713,714.66, representing a year-on-year increase of 96.20%[31]. - The net profit attributable to shareholders was CNY 613,941,073.84, up 56.67% compared to the same period last year[31]. - The company achieved a revenue of 1.62 billion CNY in the first half of 2022, representing a year-on-year growth of 96.20%[164]. - Net profit attributable to shareholders reached 614 million CNY, an increase of 56.67% compared to the previous year[164]. - Sales revenue from COVID-19 related businesses, including diagnostic raw materials and test kits, amounted to 1.172 billion CNY, a year-on-year increase of approximately 121.79%[164]. User Growth and Market Expansion - User data showed an increase in active users, with the total number of users growing to 1.2 million, up 30% compared to the same period last year[2]. - The company is expanding its market presence, targeting an increase in market share by 15% in the next year through strategic partnerships and marketing initiatives[2]. - Market expansion plans include entering three new international markets by the end of the fiscal year, targeting a 20% increase in global sales[21]. - The company has established a marketing network covering over 2,200 medical institutions across more than 30 provinces and cities in China, with ongoing international expansion efforts[163]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 100 million in revenue, with three new products set to be released by the end of Q3 2022[2]. - The company has developed over 200 types of gene-engineered recombinant enzymes and more than 1,000 high-performance antigens and monoclonal antibodies available for various applications[38]. - The company has launched new drug research reagents and vaccine evaluation reagents, including the Add&ReadTM series, which are compatible with high-throughput operations[42]. - The company has developed over 100 new products annually, leveraging its multi-disciplinary technology platforms in molecular biology, immunology, and enzymology[151]. - The company has developed a series of detection products for mRNA process residuals, becoming the first domestic manufacturer to achieve this from raw materials to end products[171]. Research and Development - Research and development investments have increased by 40%, focusing on innovative technologies and product enhancements to maintain competitive advantage[2]. - The company invested a total of 419 million CNY in R&D over the past three years, with 157 million CNY in the reporting period, representing an increase of approximately 85.72% compared to the same period in 2021, and an R&D expense ratio of about 9.69%[104]. - R&D expenses for the reporting period reached 157 million, a year-on-year increase of 85.72%, with R&D expenses accounting for 12.34% of total revenue[154]. - The company has established a dedicated R&D base of approximately 27,000 square meters, providing substantial support for its research activities[154]. Sustainability and Operational Efficiency - The management highlighted a commitment to sustainability, with plans to reduce operational costs by 10% through energy-efficient practices by the end of 2022[2]. - The company is focusing on enhancing its supply chain efficiency, aiming to reduce costs by 15% over the next year[21]. - The company has implemented automation in key production processes to enhance product quality and reduce operational errors[68]. Risks and Challenges - No significant risks were identified that could impact the company's operations during the reporting period, ensuring stability for stakeholders[2]. - The company is exposed to risks related to product development, including potential failures due to high costs or slow progress in R&D[190]. - The company faces risks from industry policy changes, including the "two-invoice system" and volume-based procurement, which could impact operational performance[199]. - Global economic pressures and uncertainties related to the COVID-19 pandemic may adversely affect the company's domestic and international business operations[200]. Compliance and Certifications - The company has received multiple medical device registration certificates, indicating a strong commitment to compliance and product quality since 2017[1][2][3]. - The company has completed ISO 13485 certification for its medical device quality management system, enhancing its quality assurance capabilities[185]. - The company has received CE certification for multiple COVID-19 related products, including the SARS-CoV-2 and Influenza A/B Virus Antigen Combined Detection Kit, certified in December 2020[134].

Financial Performance - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares, totaling approximately 12,000.30 million RMB, which represents 17.69% of the net profit attributable to shareholders for the year 2021[7]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development[5]. - The company reported a significant increase in revenue, reaching 1.2 billion RMB, representing a 25% year-over-year growth[22]. - The company's operating revenue for 2021 was approximately ¥1.87 billion, representing a year-over-year increase of 19.44% compared to ¥1.56 billion in 2020[33]. - Net profit attributable to shareholders decreased by 17.46% year-over-year to approximately ¥678 million, down from ¥822 million in 2020[32]. - The net profit after deducting non-recurring gains and losses fell by 20.90% to approximately ¥644 million from ¥814 million in the previous year[32]. - The company's total assets increased by 185.87% year-over-year to approximately ¥4.61 billion, compared to ¥1.61 billion at the end of 2020[33]. - The net assets attributable to shareholders grew by 209.77% year-over-year to approximately ¥4.13 billion, up from ¥1.33 billion in 2020[33]. - Basic earnings per share decreased by 19.05% to ¥1.87 from ¥2.31 in 2020[35]. - The net cash flow from operating activities decreased by 23.24% to approximately ¥617 million, down from ¥804 million in 2020[33]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 12.33%, up from 8.02% in the previous year, indicating a rise of 4.31 percentage points[35]. - R&D investment totaled ¥23,032.15 million, an increase of 83.47% compared to the previous year[180]. - R&D investment accounted for 12.33% of total revenue, up by 4.31 percentage points from 8.02% in the previous year[180]. - The company has launched over 200 new products covering life sciences, biomedicine, and in vitro diagnostics, with 652 R&D personnel accounting for 27.39% of the total workforce, and over 50% of R&D staff holding a master's degree or higher[136]. - The company has developed over 800 terminal products and 62 types of POCT diagnostic reagents, with 42 products obtaining Chinese medical device registration[198]. - The company has successfully developed 10 new products and obtained 3 invention patents in the real-time fluorescence quantitative PCR enzyme raw material development project, with a total investment of 187 million yuan[185]. - The company has completed the development of a new coronavirus variant detection antibody, achieving high sensitivity for all variants, with a total investment of 300 million yuan[185]. - The company has developed a complete mRNA quality analysis method and established a platform for mRNA vaccine development, enhancing its response capabilities for customer needs[163]. - The company has expanded its R&D team to 652 members, a year-on-year increase of 56.73%[50]. - The company has filed for 62 new patents, including 37 invention patents and 9 utility model patents, during the reporting period[164]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[22]. - The company is focusing on expanding its product offerings and optimizing customer service experience to increase market share in the life sciences sector[57]. - The company has established a sales network covering over 2,200 medical institutions, including hospitals and third-party testing centers[58]. - The company has established a sales system combining distribution and direct sales to expand its international market presence[64]. - The company is actively pursuing partnerships and collaborations to further its market expansion and product development strategies[173]. - The company is focusing on market expansion through new product launches and strategic partnerships to enhance its competitive position[179]. - The company has established a marketing strategy focused on "embedding R&D to address pain points," aiming for long-term partnerships with clients[64]. - The company has received regulatory approvals for various test kits, enhancing its market presence and product offerings[169]. Product Development and Innovation - New product launches included a novel antibody testing kit, expected to contribute an additional 200 million RMB in revenue[22]. - The company has developed over 800 types of biological reagents, with applications in scientific research, high-throughput sequencing library construction, molecular diagnostics, and animal quarantine, serving over 1,000 research institutions and 1,400 high-throughput sequencing service companies[54]. - The company has developed a series of multi-indicator detection products, including three cardiac markers (hscTnT/CK-MB/MYO) and two inflammation markers (PCT/IL-6), which meet clinical demands for high-quality testing products[159]. - The company has developed POCT diagnostic reagents across eight series, including cardiovascular, inflammation, reproductive health, gastric function, autoimmune, renal function, chronic disease management, and respiratory diseases, enhancing early diagnosis capabilities[78]. - The company has developed over 200 customized enzymes through its protein engineering platform, achieving international advanced levels in enzyme activity, catalytic efficiency, stability, specificity, and tolerance[150]. - The company has developed a comprehensive solution for COVID-19 detection, including core enzymes and antibody raw materials, with products sold in over 30 countries and regions[136]. - The company has launched multiple diagnostic test kits, including the Heart-type Fatty Acid Binding Protein Test Kit and Myoglobin Test Kit, approved in March 2017[169]. - The company has developed a range of quality control products and calibration standards to ensure the accuracy of its diagnostic tests[169]. Regulatory Compliance and Quality Management - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of its financial statements[6]. - The company has obtained 105 medical device registration certificates, including 78 for Class II and Class III medical devices, and has applied for overseas market access for over ten COVID-19 testing products in around 200 countries[58]. - The company has strengthened its quality management system and optimized production processes to enhance product quality[67]. - The company has established a technology innovation center in collaboration with Fudan University, focusing on high-throughput sequencing library preparation quality standards[157]. - The company has achieved CE certification for its subsidiary, Novozan Medical, indicating compliance with European health and safety standards[174]. Industry Trends and Market Outlook - The global life sciences research funding increased from $116.6 billion in 2015 to $151.4 billion in 2019, with a CAGR of 6.7%[1]. - The global biological research reagent market size reached $12.8 billion in 2015 and grew to $17.5 billion in 2019, with a CAGR of 8.1%[1]. - The molecular diagnostics market in China grew from 3.1 billion RMB in 2015 to 8.4 billion RMB in 2019, with a CAGR of 28.5%, and is projected to reach 23.8 billion RMB by 2024, representing a CAGR of 23.2% from 2019 to 2024[146]. - The aging population and the rise of chronic diseases are expected to further boost the demand for in vitro diagnostic products and biomedicine[144]. - The overall market outlook remains positive, with expectations for continued growth driven by increased healthcare demand[179].

Financial Performance - The company's operating revenue for Q1 2022 was ¥975,338,224.30, representing an increase of 80.07% compared to the same period last year[5] - The net profit attributable to shareholders was ¥431,359,400.13, reflecting a growth of 28.18% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥412,503,311.93, up by 25.79% from the previous year[5] - Total operating revenue for Q1 2022 reached ¥975,338,224.30, a significant increase of 80.0% compared to ¥541,639,956.10 in Q1 2021[38] - Net profit for Q1 2022 was ¥431,359,398.28, representing a 28.2% increase from ¥336,514,049.65 in Q1 2021[39] - Basic and diluted earnings per share for Q1 2022 were both ¥1.08, compared to ¥0.93 in Q1 2021[39] Expenses - Research and development expenses totaled ¥71,157,250.07, which is an increase of 86.32% compared to the same period last year[7] - Total operating costs for Q1 2022 were ¥459,987,180.50, up 200.0% from ¥153,038,269.99 in Q1 2021[38] - Research and development expenses for Q1 2022 were ¥71,157,250.07, up 86.4% from ¥38,191,518.13 in Q1 2021[38] - Sales expenses for Q1 2022 amounted to ¥89,918,252.50, an increase of 88.0% compared to ¥47,806,170.60 in Q1 2021[38] - The company reported a significant increase in sales expenses, which reached ¥65,710,671.29 in Q1 2022, compared to ¥26,881,353.05 in Q1 2021, an increase of 144.5%[56] Cash Flow - The cash flow from operating activities showed a net outflow of ¥72,730,459.02, a decrease of 69.29% year-over-year[5] - Cash inflow from operating activities for Q1 2022 was CNY 974,826,717.20, a significant increase from CNY 521,555,553.48 in Q1 2021, representing a growth of approximately 86.9%[44] - Cash outflow from operating activities totaled CNY 902,096,258.18 in Q1 2022, compared to CNY 284,723,116.95 in Q1 2021, indicating a rise of about 216.5%[44] - Net cash flow from operating activities decreased to CNY 72,730,459.02 in Q1 2022 from CNY 236,832,436.53 in Q1 2021, reflecting a decline of approximately 69.3%[44] - The company reported a cash outflow from financing activities of CNY 9,929,413.42 in Q1 2022, indicating a significant cash drain compared to the previous period[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,458,970,212.67, marking an 18.49% increase from the end of the previous year[7] - Total liabilities increased to ¥898,453,471.96 in Q1 2022, up from ¥479,829,915.56 in Q1 2021, reflecting a growth of 87.2%[38] - Total equity attributable to shareholders reached ¥4,560,516,742.64 in Q1 2022, compared to ¥4,127,289,969.06 in Q1 2021, an increase of 10.5%[38] - The total assets reached ¥5,458,970,212.67 in Q1 2022, up from ¥4,607,119,884.54 in Q1 2021, indicating a growth of 18.5%[38] - The total assets of the company increased to CNY 4,723,259,498.58 as of March 31, 2022, compared to CNY 4,369,881,732.97 at the end of 2021, marking an increase of approximately 8.1%[50] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,557, with the top 10 shareholders holding 72.07% of shares[15] - The largest shareholder, Nanjing Nuowei Investment Management Co., Ltd., holds 161,907,305 shares, accounting for 40.48%[15] - The company has a total of 161,907,305 shares pledged, representing 4.01% of the total shares[15] Inventory and Receivables - The company reported a significant increase in accounts receivable by 57.90%, attributed to expanded sales scale and increased revenue[10] - The inventory increased by 72.20%, driven by the company's expansion in operations to meet market demand[10] - Accounts receivable increased to CNY 386,709,326.28 in Q1 2022 from CNY 290,646,656.10 in Q1 2021, representing a rise of approximately 33.0%[50] - Inventory levels rose to CNY 152,751,118.26 in Q1 2022, compared to CNY 125,723,302.93 in Q1 2021, reflecting an increase of about 21.5%[50] Investment Activities - The company established a wholly-owned subsidiary, Nanjing Nuowei Health Technology Co., Ltd., with a registered capital of ¥10 million to focus on synthetic biology raw material R&D and sales[28] - Net cash flow from investing activities was negative CNY 704,516,251.22 in Q1 2022, worsening from negative CNY 253,654,182.38 in Q1 2021[46] - The company's investment activities generated cash inflows of ¥1,179,456,011.83 in Q1 2022, down from ¥1,611,838,987.79 in Q1 2021[58] - Net cash flow from investment activities was -403,401,918.52, compared to -270,835,118.88 in the previous period, indicating a decline in investment performance[60]